Log in

NYSEAMERICAN:SYNSynthetic Biologics Stock Price, Forecast & News

$0.54
+0.03 (+5.50 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.51
Now: $0.54
$0.54
50-Day Range N/A
52-Week Range
$0.25
Now: $0.54
$0.64
Volume92,400 shs
Average Volume376,669 shs
Market Capitalization$9.88 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases, and monoclonal antibody therapies that prevents and treats pertussis. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Read More
Synthetic Biologics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees13
Market Cap$9.88 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Synthetic Biologics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Synthetic Biologics.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Synthetic Biologics.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEAMERICAN:SYN) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.07. View Synthetic Biologics' earnings history.

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Synthetic Biologics's stock reverse split on Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for SYN?

2 brokerages have issued 12 month price targets for Synthetic Biologics' stock. Their forecasts range from $1.25 to $1.50. On average, they anticipate Synthetic Biologics' stock price to reach $1.38 in the next year. This suggests a possible upside of 154.1% from the stock's current price. View analysts' price targets for Synthetic Biologics.

Has Synthetic Biologics been receiving favorable news coverage?

Media stories about SYN stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synthetic Biologics earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Synthetic Biologics.

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 58)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Vince Wacher, Head of Product and Corp. Devel.
  • Dr. Michael Kaleko, Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.54.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $9.88 million. Synthetic Biologics employs 13 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.